glp-1 neuroinflammation Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology GLP-1s are reinforcing a principle

Nath et al

In this post: Understanding Scale Fluctuations in Your GLP-1 Weight Loss Progress The first step to a healthier relationship with your scales is understanding that they are merely devices measuring your total body mass at a specific moment

It also cites a figure of roughly 30 to 40% of patients having significant gastrointestinal side effects in the first four to eight weeks, though it names no research behind that range

In a 26-week rat oral toxicity study, AOD-9604 produced dose-dependent changes in serum osteocalcin (a bone-turnover marker) at week 13, with the direction reversing by week 26

The GLP-1 market is evolving rapidly, with innovation driving progress while introducing new clinical and regulatory challenges specially around compounded formulations and reimbursement limitations